Neonatal Med Search


Neonatal Med > Volume 20(3); 2013 > Article
Neonatal Medicine 2013;20(3):343-353.
DOI:    Published online October 29, 2013.
Therapeutic Application of Neural Stem Cells for Neonatal Hypoxic-ischemic Brain Injury.
Kook In Park, Kyoyeon Goo, Kwangsoo Jung, Miri Kim, Il Sun Kim, Seokhwan Yun, Il Shin Lee, Jeong Eun Shin, Ha Yang Yu, Ho Seon Eun, Jung Eun Kim, Ran Namgung, Chul Lee
1Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
2BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Neural stem cells (NSCs) are characterized by a capacity for self-renewal, differentiation into multiple neural cell lineages, and migration toward damaged sites in the central nervous system (CNS). NSCs expanded in culture could be implanted into the brain where they integrate into host neural circuitry and stably express foreign genes. It hence appears that transplantation of NSCs has been proposed as a promising therapeutic strategy in neurological disorders. During hypoxic-ischemic (HI) brain injury, factors are transiently elaborated to which NSCs respond by migrating to degenerating regions and differentiating towards replacement of dying neural cells. In addition, NSCs serve as vehicles for gene delivery and appear capable of simultaneous neural cell replacement and gene therapy (e.g. with factors that might enhance neuronal differentiation, neurites outgrowth, proper connectivity, neuroprotection, and/or immunomodulatory substances). When combined with certain synthetic biomaterials, NSCs may be even more effective in 'engineering' the damaged CNS towards reconstitution. Human NSCs were isolated from the forebrain of an aborted fetus at 13 weeks of gestation and were grown as neurospheres in cultures. After the characterization of human NSCs in preclinical testing and the approval of the IRB, a clinical trial of the transplantation of human NSCs into patients with severe perinatal HI brain injury has been performed. The existing data from these clinical trials have shown to be safe, well tolerated, and of neurologically-some benefits. Therefore, long-term and large scale multicenter clinical study is required to determine its precise therapeutic effect and safety.
Key Words: Neural stem cells, Neonatal hypoxic-ischemic brain injury, Cell therapy


Browse all articles >

Editorial Office
34, Sajik-ro 8–gil(King’s Gargen 3 Block 1207), Jongno-gu, Seoul 03174, Republic of Korea
Tel: +82-2-730-1993    Fax: +82-2-730-1994    E-mail:                

Copyright © 2022 by The Korean Society of Neonatology.

Developed in M2PI

Close layer
prev next